InvestorsHub Logo
Followers 15
Posts 1517
Boards Moderated 0
Alias Born 12/13/2009

Re: Joseph_K post# 457003

Thursday, 04/18/2024 7:54:00 PM

Thursday, April 18, 2024 7:54:00 PM

Post# of 459685

We don't even know if the promised journal article has been accepted anywhere.



The April 2024 Corporate Presentation states "Data from the blarcamesine Phase 2b/3 ANAVEX®2-73-AD-004 trial to be published in an upcoming peer-reviewed journal". To me, that certainly implies that an article has been accepted. I suppose a more cynical view is that the statement only expresses AVXL's intentions. The SEC filings don't address a journal article at all so far as I remember.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News